Fortress Biotech Q1 net income jumps on PRV sale

Fortress Biotech

14/05/2026 21:20

Overview

US biopharma firm reported Q1 net income of $108.4 mln after PRV sale

Q1 revenue rose yr/yr to $16 mln but missed sole analyst estimate

Company reduced debt and cash rose to $256 mln after PRV proceeds

Outlook

Company expects increasing royalty revenue from ZYCUBO and UNLOXCYT

Fortress anticipates potential milestone payments from partnered assets, including regulatory submissions for anselamimab

Company says it is well positioned to advance strategic initiatives and drive long-term value

Result Drivers

PRV SALE - Net income driven by $205 mln gain from Rare Pediatric Disease Priority Review Voucher sale

PRODUCT REVENUE GROWTH - Higher Q1 revenue mainly from increased sales at Journey Medical

LOWER OPERATING EXPENSES - Reduced R&D and SG&A costs contributed to improved profitability

Company press release: ID:nGNXVk1hX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$16.03 mln
$16.34 mln (1 Analyst)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Fortress Biotech Inc is $10.75, about 382.1% above its May 13 closing price of $2.23

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 310 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)